Phenotypes associated with this allele
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Ercc6tm1Gvh mutation
(1 available);
any
Ercc6 mutation
(78 available)
Tg(Camk2a-cre)1Szi mutation
(0 available)
Xpatm1Gvh mutation
(0 available);
any
Xpa mutation
(22 available)
Xpatm1Hvs mutation
(4 available);
any
Xpa mutation
(22 available)
|
|
|
Dilated ventricles and brain atrophy in Ercc6tm1Gvh/Ercc6tm1Gvh Xpatm1Gvh/Xpatm1Hvs Tg(Camk2a-cre)1Szi/0 mice
mortality/aging
|
|
• between 12 and 22 months
|
nervous system
|
|
• from 9 to 12 months of age, mice exhibit seizure behavior characterized by episodes of immobility unlike control mice
|
|
|
• at 6 to 12 months of age, mice exhibit atrophy in the telencephalon (cortex, hippocampus, caudate-putamen and septum) unlike control mice
|
|
|
• atrophic at 6 to 12 months of age
|
|
|
• atrophic at 6 to 12 months of age
|
|
|
• mild atrophy at 6 months of age
• severe atrophy in older mice
|
|
|
• at 6 to 12 months of age
|
behavior/neurological
|
|
• from 9 to 12 months of age, mice exhibit seizure behavior characterized by episodes of immobility unlike control mice
|
growth/size/body
|
|
• at 9 to 12 months of age
|
|
|
• at 9 to 12 months of age
|
immune system
hematopoietic system
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Htttm1Szi mutation
(0 available);
any
Htt mutation
(179 available)
Htttm2Szi mutation
(0 available);
any
Htt mutation
(179 available)
Tg(Camk2a-cre)1Szi mutation
(0 available)
|
|
|
mortality/aging
|
|
• die between 11 and 13 months of age
|
growth/size/body
|
|
• smaller than controls at weaning and at P60
|
behavior/neurological
|
|
• abnormal limb clasping at P60 that becomes progressively more severe such that mice curl their body upon clasping and maintain the posture for several seconds following return to cage
|
|
|
• exhibit a slight tremor at 10-12 months of age
|
|
|
• exhibit motor defects in mutants subjected to cage-top rotation test and elevated wire rod hanging test
|
|
|
• noticeably hypoactive at 10-12 months of age
|
nervous system
|
|
• gliosis is seen throughout the forebrain in older mutants
|
|
|
• reactive astocytosis in the entorhinal cortex, striatum, and frontal cortex at 4 and 10 months of age
|
|
|
• 4 and 8 month old mutants exhibit neurodegeneration in the external capsule fibre tracts and in fibre bundles of the internal capsule within the striatum, in the amygdala and in both the frontal and dorsal cortex
|
reproductive system
 |
• exhibit a reduction in the number of spermatocytes and round spermatids in the seminiferous tubules and in mature motile sperm in the lumen of the epididymis
|
|
|
• disorganized and contain fewer spermatocytes and round spermatids compared to controls
|
|
|
• testis is about 50% the weight of controls
|
endocrine/exocrine glands
|
|
• disorganized and contain fewer spermatocytes and round spermatids compared to controls
|
|
|
• testis is about 50% the weight of controls
|
cellular
|
|
• exhibit a reduction in the number of spermatocytes and round spermatids in the seminiferous tubules and in mature motile sperm in the lumen of the epididymis
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Bdnftm1Sieg mutation
(0 available);
any
Bdnf mutation
(41 available)
Tg(Camk2a-cre)1Szi mutation
(0 available)
|
|
|
nervous system
|
|
• significant decrease in the magnitude of LTP induced by 200 Hz tetanic stimulation, such that the mean field EPSP measured 1 hour after induction of LTP is enhanced to only 145% of its pretetanus level in mutants compared to 198% enhancement in controls
• the enhancement of FM 1-43 (a fluorescent marker of synaptic vesicle cycling) release from presynaptic terminals seen in controls during high-frequency (200 Hz) tetanic stimulation is blocked in mutants; rate of FM 1-43 release during low-frequency (50 Hz) tetanic stimulation is normal
• mutants exhibit a smaller magnitude of LTP 1 hour following theta burst stimulation, with an enhancement in the fEPSP to 136.7% of it's initial value compared to 166% in controls
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Rap1atm1Morz mutation
(2 available);
any
Rap1a mutation
(23 available)
Rap1btm1Morz mutation
(2 available);
any
Rap1b mutation
(32 available)
Tg(Camk2a-cre)1Szi mutation
(0 available)
|
|
|
nervous system
|
|
• protein levels of Rap1 are reduced by 89.4% in the cortex and 38.7% in the thalamus
|
|
|
• synaptic efficacy in cortical but not thalamic input to the lateral amygdale is 2.5-fold higher than in wild-type mice
• current-voltage relationships for AMPAR and NMDAR currents are similar to wild-type mice
|
|
|
• in the cortico-amygdala pathway, spike-timing-dependent LTP was substantially reduced with only 2 of 7 cells showing a LTP response compared to 8 of 11 cells from wild-type
|
|
|
• EPSC evoked by minimal stimulation of cortical inputs into the lateral amygdale reveals increased release of glutamate
|
|
|
• mice do not demonstrate PPF in cortical inputs to the lateral amygdale before or after long-term potentiation
|
behavior/neurological
|
|
• mice have reduced fear learning as measured by freezing to a conditioned stimulus both 3 hours and 48 hours after training with a moderately adversive unconditioned stimulus
• there is no difference in fear learning compared to wild-type mice when a more severe unconditioned stimulus is used in training
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Adora2atm1Dyj mutation
(1 available);
any
Adora2a mutation
(36 available)
Tg(Camk2a-cre)1Szi mutation
(0 available)
|
|
|
behavior/neurological
|
|
• in response to the adenosine (A2a) agonist KW-6002, locomotion is induced in male control animals but not in conditional knockout mice
• enhancement of fine movement behavior in controls is observed in response to amphetamine treatment but not in knockouts
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Adora2atm1.1Dyj mutation
(0 available);
any
Adora2a mutation
(36 available)
Adora2atm1Dyj mutation
(1 available);
any
Adora2a mutation
(36 available)
Tg(Camk2a-cre)1Szi mutation
(0 available)
|
|
|
behavior/neurological
|
|
• daily treatment with amphetamine enhances locomotor responses in male control mice but does not affect male mutants; 1 week after cessation of treatment robust locomotor sensitization persists in controls
|
|
|
• control mice exhibit greater locomotor response when treated with a Grm5 antagonist, MPEP, than forebrain-specific knockout mice
(J:102700)
• in response to the adenosine (A2a) agonist KW-6002, locomotion is induced in male control animals but not in conditional knockout mice
(J:104338)
• enhancement of fine movement behavior in male controls is observed in response to amphetamine treatment but not in knockouts
(J:104338)
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Hif1atm3Rsjo mutation
(3 available);
any
Hif1a mutation
(48 available)
Tg(Camk2a-cre)1Szi mutation
(0 available)
|
|
|
mortality/aging
|
|
• following transient middle cerebral artery occlusion
|
nervous system
|
|
• mice exhibit a slight reduction in cerebral cortex microvascular density compared with Hif1atm3Rsjo homozygotes
|
|
|
• following bilateral common carotid artery occlusion, mice exhibit decreased neuronal damage compared to in similarly treated Hif1atm3Rsjo homozygotes
|
|
|
• following transient middle cerebral artery occlusion, mice exhibit increased infarct size, increased neurological deficit scores, and mortality compared with similarly treated Hif1atm3Rsjo homozygotes
|
|
|
• 4 days after transient middle cerebral artery occlusion, infarct size is larger than in similarly treated Hif1atm3Rsjo homozygotes
• the neuroprotective effects on infarct size and neurological deficit scores of 3,4-dihydroxybenzoic acid, deferoxamine (DFO), and DP following transient middle cerebral artery occlusion is decreased compared to in similarly treated Hif1atm3Rsjo homozygotes
• however, mice still respond to neuroprotective hypoxia with reduced infarct volume at shorter exposure periods than wild-type mice
|
homeostasis/metabolism
behavior/neurological
|
|
• following transient middle cerebral artery occlusion, mice exhibit increased neurological deficit scores compared with similarly treated Hif1atm3Rsjo homozygotes
• the neuroprotective effects on infarct size and neurological deficit scores of 3,4-dihydroxybenzoic acid, deferoxamine (DFO), and DP following transient middle cerebral artery occlusion is decreased compared to in similarly treated Hif1atm3Rsjo homozygotes
|
cardiovascular system
|
|
• mice exhibit a slight reduction in cerebral cortex microvascular density compared with Hif1atm3Rsjo homozygotes
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Oxtrtm1.1Wsy mutation
(1 available);
any
Oxtr mutation
(40 available)
Tg(Camk2a-cre)1Szi mutation
(0 available)
|
|
|
growth/size/body
|
|
• weigh less than control mice
• weight discrepancy relative to controls increases with age
|
endocrine/exocrine glands
behavior/neurological
|
|
• less time spend by males investigating either familiar or novel females during second trials
• 5-trial recognition studies indicated no difference between mutant mice and controls
|
Analysis Tools